Last updated: February 20, 2026
Chloramphenicol, marketed as Chloromycetin, is an antibiotic used to treat serious bacterial infections. Its production involves sourcing bulk APIs through multiple international suppliers, with a history of manufacturing both domestically (primarily in China and India) and via contract manufacturing organizations (CMOs).
Global API Manufacturing Landscape for Chloramphenicol
Leading Suppliers
| Supplier Country |
Notable Companies |
Capacity |
Certification & Quality Standards |
Notes |
| China |
Zhejiang Tianyi Pharmaceutical Co., Ltd., Henglian Pharmaceutical Co., Ltd. |
Large-scale |
GMP, DMF filings |
Dominates production, export to global markets |
| India |
Raptakos Brett & Co. Ltd., Micro Labs Ltd. |
Moderate to large |
WHO GMP, USDMF |
Significant share in generic APIs |
| Germany |
Bayer AG |
Limited |
Approved for proprietary use |
Rare authorized production; mostly legacy |
| United States |
Par Pharmaceutical |
Limited |
US FDA-approved manufacturing |
Access through specialized suppliers |
API Source Characteristics
-
Manufacturing Quality: Most Chinese and Indian API sources comply with current Good Manufacturing Practices (GMP). Some suppliers have Drug Master Files (DMFs) filed with regulatory agencies handling global distribution.
-
Production Capacity: Chinese suppliers have capacity exceeding 10 metric tons annually, with Indian suppliers ranging from 2 to 5 metric tons annually for chloramphenicol APIs.
-
Certifications: Certifications include GMP approval, ISO standards, and sometimes USFDA or EMA filings, depending on the target export market.
Sourcing Trends & Considerations
- Regulatory Acceptance: Suppliers with US FDA, EMA, or Japan PMDA filings gain preference in North American, European, and Japanese markets.
- Supply Chain Risks: China and India supply over 90% of global API volume for chloramphenicol. Supply disruptions could impact availability.
- Counterfeit Concerns: Counterfeit APIs pose risks; verifying supplier certifications and conducting audits are essential.
Regulatory and Certification Milestones
- FDA DMF Filings: Several Chinese and Indian manufacturers have USDMFs, facilitating export to US markets.
- European Market: Suppliers with EMA compliance are prioritized for European supply chains.
- Export Restrictions: Some countries restrict chloramphenicol due to safety concerns, influencing sourcing from authorized suppliers only.
Key Sources Summary
- Chinese Suppliers: Zhejiang Tianyi Pharmaceutical, Henglian Pharmaceutical
- Indian Suppliers: Raptakos Brett & Co., Micro Labs
- Western Suppliers: Bayer AG, Par Pharmaceutical (limited)
Conclusion
Supply of bulk chloramphenicol API primarily originates from Chinese and Indian manufacturers with GMP certification and DMF filings. Western manufacturers have limited capacity, mainly supplying proprietary or specialty needs. Suppliers with recognized certifications and regulatory filings dominate the global supply chain, with Chinese suppliers holding the largest market share.
Key Takeaways
- Chinese and Indian companies dominate API production for chloramphenicol.
- Regulatory compliance and certification are critical for market entry.
- Supply chains are concentrated; disruptions could impact global availability.
- Western manufacturers have limited capacity; sourcing is often through authorized Chinese or Indian suppliers.
- Due diligence, including certification verification and supply chain monitoring, remains essential.
FAQs
1. Are Chinese API suppliers reliable for chloramphenicol?
Yes, major Chinese API manufacturers have GMP compliance and DMFs filed with regulatory agencies, supporting reliable supply for global markets.
2. What certifications should I verify when sourcing from India?
Verify GMP certification, WHO-GMP status, and any USFDA or EMA filings to ensure quality standards.
3. Is domestic production of chloramphenicol API common in Europe?
European production is limited; most supply is imported from China and India. Some Western companies may have proprietary manufacturing, but capacity remains limited.
4. How do regulatory restrictions impact API sourcing?
Restrictions in certain countries require sourcing from suppliers with proper certifications, especially for APIs like chloramphenicol associated with safety concerns.
5. What are the risks associated with sourcing chloramphenicol API?
Risks include supply disruptions, counterfeit products, and regulatory non-compliance. Conduct thorough supplier audits and verify certifications.
Sources:
- U.S. Food and Drug Administration. (2021). Drug Master Files (DMF). https://www.fda.gov/drugs/pharmaceutical-quality-resources/drug-master-files
- Chinese Pharmaceutical Industry. (2022). API Manufacturing Overview. China Pharmaceutical Review.
- Indian Pharmaceutical Industry. (2021). API Production Capacity & Standards. Pharmabiz.
- European Medicines Agency. (2022). Regulatory Guidance for Raw Materials. EMA.
- MarketWatch. (2023). Global API Market Estimates.
